
  
    
      
        Arthur_NNP Caplan_NNP 's_POS Viewpoint_NN :_: Nobody_NN Is_VBZ Perfect—_NNP But_CC Why_WRB Not_RB Try_VB to_TO Be_VB Better_NNP ?_.
        Perfection_NNP has_VBZ come_VBN in_IN for_IN a_DT lot_NN of_IN bad_JJ press_NN recently_RB ._. A_DT torrent_NN of_IN books_NNS and_CC articles_NNS
        has_VBZ recently_RB appeared_VBN [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ,_, all_DT raising_VBG serious_JJ ethical_JJ questions_NNS about_IN the_DT
        wisdom_NN and_CC morality_NN of_IN trying_VBG to_TO use_VB biomedical_JJ knowledge_NN to_TO perfect_JJ ourselves_PRP or_CC our_PRP$
        offspring_NN ._.
        Biomedical_NNP scientists_NNS and_CC physicians_NNS might_MD be_VB inclined_VBN to_TO ignore_VB this_DT literature_NN as_RB just_RB
        so_RB much_RB abstract_JJ philosophical_JJ handwringing_VBG ._. After_IN all_DT ,_, it_PRP is_VBZ almost_RB impossible_JJ to_TO find_VB
        mainstream_NN scientists_NNS arrogant_JJ enough_RB to_TO proclaim_VB their_PRP$ interest_NN in_IN perfecting_VBG anything_NN ,_,
        much_RB less_JJR themselves_PRP or_CC their_PRP$ fellow_NN human_JJ beings_NNS ._.
        Beating_NNP up_RB on_IN the_DT pursuit_NN of_IN perfection_NN is_VBZ silly_JJ ._. As_IN Salvadore_NNP Dali_NNP famously_RB pointed_VBD
        out_IN ,_, “ Have_VBP no_DT fear_NN of_IN perfection—you_NN 'll_MD never_RB reach_VB it_PRP ._.” Critics_NNS of_IN those_DT who_WP allegedly_RB
        seek_VBP to_TO perfect_JJ human_JJ beings_NNS know_VBP this_DT ._. While_IN often_RB couching_VBG their_PRP$ critiques_NNS in_IN language_NN
        that_IN assails_NNS the_DT pursuit_NN of_IN perfection_NN ,_, what_WP they_PRP really_RB are_VBP attacking_VBG is_VBZ the_DT far_RB more_RBR
        oft-expressed—albeit_JJ far_RB less_JJR lofty—desire_NN to_TO improve_VB or_CC enhance_VB a_DT particular_JJ behavior_NN or_CC
        trait_NN by_IN the_DT application_NN of_IN emerging_VBG biomedical_JJ knowledge_NN in_IN genetics_NNS ,_, neuroscience_NN ,_,
        pharmacology_NN ,_, and_CC physiology_NN ._. Those_DT who_WP might_MD accurately_RB be_VB termed_VBN “ anti-meliorists_JJ” wonder_VBP
        how_WRB we_PRP will_MD ever_RB resist_VB the_DT obvious_JJ temptation_NN to_TO put_VB this_DT knowledge_NN to_TO use_VB to_TO alter_VB
        ourselves_PRP ._. They_PRP are_VBP quick_JJ to_TO note_VB that_IN we_PRP have_VBP already_RB given_VBN in_IN to_TO such_JJ temptation—we_NN
        augment_VB our_PRP$ breasts_NNS ,_, smooth_JJ our_PRP$ wrinkles_NNS ,_, and_CC pump_VB ourselves_PRP full_JJ of_IN antidepressants_NNS ._.
        Putting_VBG the_DT brakes_NNS on_IN biologically_RB driven_VBN human_JJ betterment_NN would_MD have_VB real_JJ consequences_NNS
        for_IN science_NN ._. Some_DT lines_NNS of_IN research_NN would_MD be_VB slowed_VBN or_CC restricted_VBN [_NN 3_CD ,_, 5_CD ,_, 8_CD ]_NN ._. Their_PRP$
        application_NN would_MD be_VB declared_VBN off-limits_JJ or_CC at_IN least_JJS tightly_RB regulated_VBN
        [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._.
        Why_WRB is_VBZ the_DT drive_NN to_TO improve_VB ourselves_PRP so_RB disturbing_VBG to_TO the_DT anti-meliorists_JJ ?_. Their_PRP$
        arguments_NNS cluster_NN around_IN three_CD key_JJ worries_NNS :_: that_IN the_DT pursuit_NN of_IN perfection_NN by_IN biomedical_JJ
        means_VBZ is_VBZ vain_JJ ,_, selfish_JJ ,_, and_CC unrewarding_VBG [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 6_CD ,_, 7_CD ]_NN ,_, that_IN improving_VBG ourselves_PRP is_VBZ unfair_JJ
        [_NN 1_CD ,_, 3_CD ,_, 4_CD ]_NN ,_, and_CC that_DT enhancement_NN or_CC improvement_NN violates_VBZ human_JJ nature_NN [_NN 2_CD ,_, 4_CD ,_, 5_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN and_CC may_MD
        actually_RB destroy_VB it_PRP [_NN 2_CD ,_, 5_CD ,_, 7_CD ,_, 9_CD ]_NN ._. It_PRP is_VBZ the_DT last_NN of_IN these_DT arguments_NNS that_WDT is_VBZ at_IN the_DT core_NN of_IN
        anti-meliorist_JJ concerns_NNS ._.
        It_PRP cannot_NN simply_RB be_VB the_DT pursuit_NN of_IN improvement_NN that_WDT is_VBZ making_VBG anti-meliorists_JJ nervous_JJ ._.
        Many_JJ religious_JJ traditions_NNS and_CC spiritual_NN movements_NNS seek_VBP perfection_NN [_NN 10_CD ,_, 11_CD ,_, 12_CD ,_, 13_CD ]_NN ,_, but_CC these_DT
        evoke_VBP no_DT negative_JJ commentary_NN from_IN the_DT anti-meliorists_JJ ._. Nor_CC do_VBP efforts_NNS to_TO improve_VB animals_NNS
        and_CC plants_NNS set_VBD this_DT crowd_NN aflutter_NN ._. Rather_RB ,_, it_PRP is_VBZ biomedical_JJ knowledge_NN being_VBG applied_VBN to_TO you_PRP
        and_CC me_PRP that_WDT is_VBZ the_DT crux_NN of_IN their_PRP$ concern_NN ._. They_PRP fear_VBP that_IN in_IN applying_VBG new_JJ biomedical_JJ
        knowledge_NN to_TO improve_VB human_JJ beings_NNS ,_, something_NN essential_JJ about_IN humanity_NN will_MD be_VB lost_VBN ._. If_IN
        biomedical_JJ tinkering_NN is_VBZ allowed_VBN ,_, we_PRP will_MD destroy_VB the_DT very_JJ thing_NN that_WDT makes_VBZ us_PRP human—our_NN
        nature_NN ._.
        Anti-meliorism_NNP rests_VBZ ,_, however_RB ,_, on_IN a_DT very_RB shaky_JJ foundation_NN ._. To_TO support_VB their_PRP$ position_NN ,_,
        the_DT anti-meliorists_JJ must_MD state_VB what_WP human_JJ nature_NN is_VBZ ._. They_PRP do_VBP not_RB ._. They_PRP must_MD also_RB be_VB very_RB
        clear_JJ about_IN why_WRB they_PRP see_VBP human_JJ nature_NN as_IN static_JJ ._. They_PRP are_VBP not_RB ._. And_CC they_PRP must_MD advance_VB an_DT
        argument_NN about_IN why_WRB human_JJ nature_NN ,_, which_WDT has_VBZ presumably_RB evolved_VBN in_IN response_NN to_TO an_DT enormous_JJ
        array_NN of_IN random_JJ forces_NNS ,_, tells_VBZ us_PRP anything_NN about_IN what_WP is_VBZ good_JJ or_CC desirable_JJ in_IN terms_NNS of_IN the_DT
        traits_NNS humans_NNS should_MD possess_VB ._. They_PRP cannot_NN ._.
        The_DT fight_NN over_IN whether_IN there_EX is_VBZ any_DT such_JJ thing_NN as_IN human_JJ nature_NN is_VBZ a_DT long-standing_JJ one_CD
        [_NN 14_CD ]_NN ._. But_CC one_PRP can_MD concede_VB that_IN we_PRP are_VBP shaped_VBN by_IN a_DT causally_RB powerful_JJ set_NN of_IN genetic_JJ
        influences_VBZ and_CC still_RB remain_VB skeptical_JJ as_IN to_TO whether_IN these_DT produce_NN a_DT single_JJ “ nature_NN” that_IN
        all_DT members_NNS of_IN humanity_NN possess_VBP ._. Is_VBZ there_EX a_DT single_JJ trait_NN or_CC fixed_VBN set_NN of_IN traits_NNS that_WDT
        defines_VBZ the_DT nature_NN of_IN who_WP we_PRP are_VBP and_CC have_VBP been_VBN throughout_IN our_PRP$ entire_JJ existence_NN on_IN this_DT
        planet_NN ?_. Unless_IN they_PRP can_MD articulate_VB this_DT Platonic_NNP essence_NN ,_, anti-meliorists_JJ do_VBP not_RB have_VB a_DT
        foundation_NN for_IN their_PRP$ argument_NN that_DT change_NN ,_, improvement_NN ,_, and_CC betterment_NN are_VBP grave_JJ threats_NNS to_TO
        humanity_NN ._.
        Worse_JJR still_RB for_IN anti-meliorists_JJ ,_, we_PRP are_VBP clearly_RB creatures_NNS who_WP have_VBP long_RB tinkered_VBN with_IN
        ourselves_PRP ,_, using_VBG all_DT manner_NN of_IN technologies_NNS from_IN clothing_NN to_TO telescopes_NNS to_TO computers_NNS to_TO
        airplanes_NNS ._. Our_PRP$ view_NN of_IN our_PRP$ “ nature_NN” is_VBZ closely_RB linked_VBN to_TO the_DT technologies_NNS that_IN we_PRP have_VBP
        invented_VBN and_CC to_TO which_WDT we_PRP have_VBP adapted_VBN [_NN 15_CD ]_NN ._. We_PRP are_VBP already_RB technological_JJ creatures_NNS ._.
        Nor_CC is_VBZ there_EX any_DT normative_JJ guidance_NN offered_VBN by_IN our_PRP$ evolutionary_JJ history_NN that_WDT shows_VBZ why_WRB
        we_PRP should_MD not_RB try_VB to_TO improve_VB upon_IN the_DT biological_JJ design_NN with_IN which_WDT we_PRP are_VBP endowed_VBN ._.
        Augmenting_NNP breasts_NNS or_CC prolonging_VBG erections_NNS may_MD be_VB vain_JJ and_CC even_RB a_DT waste_NN of_IN scarce_JJ
        resources_NNS ,_, but_CC seeking_VBG to_TO use_VB our_PRP$ knowledge_NN to_TO enhance_VB our_PRP$ vision_NN ,_, memory_NN ,_, learning_VBG skills_NNS ,_,
        immunity_NN ,_, or_CC metabolism_NN is_VBZ not_RB obviously_RB either_RB ._.
        Ultimately_RB ,_, anti-meliorism_JJ posits_NNS a_DT static_JJ vision_NN of_IN human_JJ nature_NN to_TO which_WDT the_DT
        anti-meliorists_JJ mandate_NN we_PRP reconcile_VB ourselves_PRP ._. If_IN anything_NN is_VBZ clear_JJ about_IN human_JJ nature_NN ,_, it_PRP
        is_VBZ that_IN this_DT is_VBZ not_RB an_DT accurate_JJ view_NN of_IN who_WP we_PRP have_VBP been_VBN or_CC what_WP we_PRP are_VBP now_RB ,_, or_CC a_DT view_NN that_WDT
        should_MD determine_VB what_WP we_PRP become_VBP ._.
      
      
        Carl_NNP Elliott_NNP 's_POS Viewpoint_NN :_: Pharma_NNP 's_POS Gain_NNP May_NNP Be_VB Our_PRP$ Loss_NN
        Those_DT of_IN us_PRP who_WP worry_VBP about_IN medical_JJ enhancement_NN are_VBP usually_RB less_RBR worried_JJ about_IN the_DT
        technologies_NNS themselves_PRP than_IN about_IN the_DT larger_JJR social_JJ effects_NNS of_IN embracing_VBG them_PRP too_RB
        enthusiastically_RB ._. Just_RB as_IN you_PRP do_VBP not_RB need_VB to_TO object_VB to_TO cars_NNS to_TO worry_VB about_IN urban_JJ sprawl_NN ,_,
        you_PRP do_VBP not_RB need_VB to_TO object_VB to_TO enhancement_NN technologies_NNS to_TO question_VB where_WRB these_DT technologies_NNS
        may_MD be_VB taking_VBG us_PRP ._. It_PRP is_VBZ not_RB just_RB technophobes_NNS who_WP wonder_VBP whether_IN a_DT society_NN that_IN consumes_NNS
        90_CD %_NN of_IN the_DT world_NN 's_POS supply_NN of_IN methylphenidate_NN (_( Ritalin_NNP )_) ,_, where_WRB the_DT most_RBS profitable_JJ class_NN of_IN
        drugs_NNS is_VBZ antidepressants_NNS ,_, and_CC where_WRB cosmetic_JJ surgeons_NNS perform_VBP liposuction_NN on_IN prime-time_JJ
        television_NN is_VBZ a_DT society_NN that_WDT has_VBZ somehow_RB lost_VBN its_PRP$ way_NN ._.
        Let_VB 's_PRP look_VB at_IN three_CD of_IN the_DT most_RBS commercially_RB successful_JJ medical_JJ enhancements_NNS of_IN recent_JJ
        years_NNS :_: selective_JJ serotonin_NN reuptake_NN inhibitors_NNS ,_, hormone_NN replacement_NN therapy_NN ,_, and_CC the_DT diet_NN
        drug_NN fenfluramine-phentermine_JJ (_( Fen-_NNP Phen_NNP )_) ._. What_WP can_MD we_PRP learn_VB from_IN these_DT interventions_NNS ?_.
        First_LS ,_, the_DT manufacturers_NNS of_IN enhancement_NN technologies_NNS will_MD usually_RB exploit_VB the_DT blurry_JJ
        line_NN between_IN enhancement_NN and_CC treatment_NN in_IN order_NN to_TO sell_VB drugs_NNS ._. Because_IN enhancement_NN
        technologies_NNS must_MD be_VB prescribed_VBN by_IN physicians_NNS ,_, drug_NN manufacturers_NNS typically_RB market_VBP the_DT
        technologies_NNS not_RB as_IN enhancements_NNS ,_, but_CC as_IN treatments_NNS for_IN newly_RB discovered_VBN or_CC
        under-recognized_JJ disorders_NNS ._. Selective_NNP serotonin_NN reuptake_NN inhibitors_NNS were_VBD marketed_VBN not_RB as_IN
        personality_NN enhancers_NNS ,_, or_CC even_RB only_RB as_IN treatments_NNS for_IN clinical_JJ depression_NN ,_, but_CC as_IN
        treatments_NNS for_IN questionable_JJ illnesses_NNS like_IN “ premenstrual_NN dysphoric_JJ disorder_NN” [_NN 16_CD ]_NN ._. Fen-_NNP Phen_NNP
        was_VBD sold_VBN not_RB as_IN a_DT mere_JJ diet_NN drug_NN but_CC as_IN a_DT treatment_NN for_IN obesity_NN ,_, which_WDT Wyeth_NNP ,_, the_DT
        manufacturer_NN ,_, portrayed_VBN as_IN a_DT dangerous_JJ public_JJ health_NN problem_NN [_NN 17_CD ]_NN ._. Estrogen_NNP replacement_NN
        therapy_NN was_VBD initially_RB marketed_VBN as_IN a_DT risk-free_JJ way_NN for_IN women_NNS to_TO extend_VB their_PRP$ youthfulness_NNS ._.
        But_CC when_WRB a_DT 1974_CD study_NN found_VBD that_DT estrogen_NN replacement_NN therapy_NN was_VBD associated_VBN with_IN an_DT
        increased_VBN risk_NN of_IN endometrial_NN cancer_NN ,_, the_DT manufacturers_NNS added_VBD progesterone_NN ,_, renamed_VBD the_DT
        combination_NN “ hormone_NN” replacement_NN therapy_NN ,_, and_CC recast_NN it_PRP as_IN a_DT treatment_NN for_IN medical_JJ
        problems_NNS associated_VBN with_IN menopause_NN such_JJ as_IN osteoporosis_NNS [_NN 6_CD ]_NN ._.
        Second_JJ ,_, an_DT alarming_JJ number_NN of_IN supposedly_RB risk-free_JJ enhancements_NNS have_VBP later_RB been_VBN
        associated_VBN with_IN unanticipated_JJ side_NN effects_NNS ,_, some_DT of_IN them_PRP deadly_JJ ._. Wyeth_NNP has_VBZ set_VBN aside_RB over_IN
        $_$ 16_CD billion_CD to_TO compensate_VB the_DT thousands_NNS of_IN patients_NNS who_WP have_VBP developed_VBN valvular_NN heart_NN
        disease_NN and_CC pulmonary_JJ hypertension_NN after_IN taking_VBG Fen-_NNP Phen_NNP [_NN 18_CD ]_NN ._. A_DT 2002_CD National_NNP Institutes_NNPS
        of_IN Health_NNP study_NN found_VBD that_DT hormone_NN replacement_NN therapy_NN was_VBD associated_VBN with_IN such_JJ an_DT elevated_VBD
        risk_NN of_IN heart_NN disease_NN ,_, stroke_NN ,_, pulmonary_JJ emboli_NN ,_, and_CC breast_NN cancer_NN that_IN the_DT study_NN was_VBD
        stopped_VBN prematurely_RB [_NN 19_CD ]_NN ._. Selective_NNP serotonin_NN reuptake_NN inhibitors_NNS are_VBP currently_RB embroiled_VBN
        in_IN controversy_NN over_IN whether_IN they_PRP are_VBP associated_VBN with_IN an_DT elevated_VBD risk_NN of_IN suicide_NN [_NN 20_CD ]_NN ._.
        Third_NNP ,_, the_DT most_RBS successful_JJ enhancement_NN technologies_NNS have_VBP been_VBN backed_VBN by_IN tremendously_RB
        influential_JJ public_JJ relations_NNS campaigns_NNS ._. These_DT campaigns_NNS have_VBP included_VBN ghostwritten_NN journal_NN
        articles_NNS ,_, industry-funded_JJ front_JJ groups_NNS ,_, and_CC lucrative_JJ payments_NNS to_TO academics_NNS ,_, professional_JJ
        societies_NNS ,_, and_CC university_NN centers_NNS [_NN 21_CD ]_NN ._. For_IN example_NN ,_, GlaxoSmithKline_NNP marketed_VBD paroxetine_NN
        (_( Paxil_NNP )_) by_IN promoting_VBG the_DT previously_RB obscure_JJ diagnosis_NN of_IN “ social_JJ anxiety_NN disorder_NN” through_IN
        phony_JJ support_NN groups_NNS ,_, celebrity_NN spokespeople_NN ,_, a_DT direct-to-consumer_JJ illness_NN awareness_NN
        campaign_NN ,_, and_CC generous_JJ payments_NNS to_TO key_VB opinion_NN leaders_NNS [_NN 22_CD ]_NN ._. The_DT manufacturers_NNS of_IN estrogen_NN
        replacement_NN therapy_NN marketed_VBD the_DT hormone_NN in_IN the_DT 1960_CD s_VBZ by_IN funding_VBG a_DT “ research_NN foundation_NN”
        for_IN Robert_NNP Wilson_NNP ,_, the_DT gynecologist_NN and_CC author_NN of_IN the_DT best-selling_JJS book_NN 
        Feminine_NNP Forever_NNP [_NN 6_CD ]_NN ._. Wyeth_NNP marketed_VBD Fen-_NNP Phen_NNP by_IN funding_VBG obesity_NN research_NN
        centers_NNS ,_, launching_VBG public_JJ fitness_NN campaigns_NNS ,_, contracting_NN with_IN a_DT medical_JJ education_NN company_NN
        to_TO produce_VB a_DT series_NN of_IN ghostwritten_NN journal_NN articles_NNS ,_, and_CC making_VBG generous_JJ payments_NNS to_TO
        academic_JJ physicians_NNS who_WP then_RB published_VBN extensively_RB and_CC testified_VBD for_IN the_DT drug_NN 's_POS safety_NN to_TO
        the_DT Food_NNP and_CC Drug_NNP Administration_NNP [_NN 17_CD ]_NN ._.
        The_DT traditional_JJ worry_VBP about_IN enhancement_NN technologies_NNS is_VBZ that_IN users_NNS of_IN the_DT technologies_NNS
        are_VBP buying_VBG individual_JJ well-being_NN at_IN the_DT expense_NN of_IN some_DT larger_JJR social_JJ good_NN ._. I_PRP may_MD improve_VB
        my_PRP$ own_JJ athletic_JJ ability_NN by_IN taking_VBG steroids_NNS ,_, but_CC I_PRP set_VBD off_IN a_DT steroid_NN arms_NNS race_NN that_WDT destroys_VBZ
        my_PRP$ sport_NN ._. I_PRP may_MD get_VB cosmetic_JJ surgery_NN for_IN my_PRP$ “ Asian_JJ eyes_NNS” or_CC use_NN skin_NN lighteners_NNS for_IN my_PRP$ dark_JJ
        skin_NN ,_, but_CC I_PRP reinforce_VBP the_DT implicitly_RB racist_JJ social_JJ norms_NNS that_WDT say_VBP that_IN Asian_JJ eyes_NNS or_CC dark_JJ
        skin_NN are_VBP traits_NNS to_TO be_VB ashamed_JJ of_IN ._. The_DT worry_VBP is_VBZ that_IN some_DT aspect_NN of_IN the_DT way_NN we_PRP live_VBP
        together_RB ,_, collectively_RB ,_, is_VBZ going_VBG to_TO be_VB damaged_VBN by_IN actions_NNS that_IN we_PRP take_VBP individually_RB
        [_NN 4_CD ]_NN ._.
        A_DT market-driven_JJ health-care_NN system_NN brings_VBZ this_DT worry_VBP much_RB closer_JJR to_TO home_NN ._. The_DT
        pharmaceutical_JJ industry_NN is_VBZ now_RB the_DT most_RBS profitable_JJ and_CC politically_RB powerful_JJ industry_NN in_IN the_DT
        United_NNP States_NNPS [_NN 23_CD ]_NN ._. It_PRP also_RB has_VBZ a_DT huge_JJ financial_JJ interest_NN in_IN creating_VBG a_DT demand_NN for_IN
        enhancement_NN technologies_NNS ._. The_DT pharmaceutical_JJ industry_NN can_MD buy_VB politicians_NNS to_TO pass_VB
        industry-friendly_JJ legislation_NN ;_: it_PRP can_MD buy_VB academic_JJ scientists_NNS to_TO publish_VB favorable_JJ journals_NNS
        articles_NNS ;_: it_PRP can_MD buy_VB professional_JJ societies_NNS and_CC patient_NN support_NN groups_NNS to_TO spread_VB the_DT word_NN
        on_IN the_DT newly_RB medicalized_JJ disorders_NNS that_IN its_PRP$ interventions_NNS are_VBP developed_VBN to_TO treat_VB [_NN 24_CD ]_NN ._. It_PRP
        can_MD even_RB buy_VB bioethicists_NNS to_TO dispense_VB with_IN any_DT moral_JJ concerns_NNS [_NN 25_CD ]_NN ._. In_IN this_DT kind_NN of_IN
        political_JJ and_CC economic_JJ climate_NN ,_, how_WRB likely_JJ is_VBZ it_PRP that_IN dissenting_JJ voices_NNS will_MD have_VB any_DT
        effect_NN before_IN it_PRP is_VBZ too_RB late_RB ?_.
      
      
        Caplan_NNP 's_POS Response_NNP to_TO Elliott_NNP 's_POS Viewpoint_NN
        Elliott_NNP professes_VBZ to_TO be_VB unhappy_JJ about_IN enhancement_NN ._. What_WP arguments_NNS does_VBZ he_PRP present_VB to_TO
        support_VB his_PRP$ unhappiness_NN ?_. Not_RB many_JJ ,_, and_CC the_DT arguments_NNS that_IN he_PRP does_VBZ offer_NN miss_VBP the_DT point_NN
        completely_RB ._.
        If_IN people_NNS want_VBP to_TO feel_VB better_JJR ,_, sleep_VB less_JJR ,_, have_VBP fewer_RBR hot_JJ flashes_NNS ,_, better_JJR vision_NN ,_, or_CC
        fewer_JJR wrinkles_NNS ,_, then_RB they_PRP may_MD want_VB to_TO use_VB enhancement_NN technologies_NNS to_TO achieve_VB these_DT things_NNS ._.
        Technology_NNP in_IN itself_PRP is_VBZ n't_RB driving_VBG us_PRP in_IN any_DT particular_JJ direction—_NN I_PRP believe_VBP that_IN we_PRP decide_VBP
        where_WRB it_PRP should_MD go_VB ._. Elliott_NNP ,_, however_RB ,_, gravely_RB warns_VBZ us_PRP that_IN you_PRP and_CC I_PRP do_VBP not_RB really_RB decide_VB
        a_DT direction_NN when_WRB it_PRP comes_VBZ to_TO matters_NNS of_IN enhancement_NN ._. It_PRP is—listen_NN carefully_RB for_IN the_DT Darth_NNP
        Vader–esque_NNP hissing—drug_NN companies_NNS !_.
        The_DT rest_NN of_IN Elliott_NNP 's_POS viewpoint_NN amounts_NNS to_TO what_WP is_VBZ his_PRP$ increasingly_RB familiar_JJ harangue_NN
        against_IN the_DT pharmaceutical_JJ industry_NN ._. The_DT drug_NN companies_NNS sucker_NN us_PRP into_IN buying_VBG enhancement_NN
        by_IN getting_VBG us_PRP hooked_JJ on_IN pseudotherapies_NNS ._. The_DT drug_NN companies_NNS rob_NN us_PRP of_IN our_PRP$ will_MD to_TO fend_VB off_RP
        their_PRP$ siren-like_JJ messages_NNS of_IN better_JJR living_VBG through_IN their_PRP$ chemistry_NN ._. And_CC the_DT drug_NN companies_NNS
        get_VBP us_PRP feeling_NN so_RB bad_JJ about_IN ourselves_PRP that_IN we_PRP empty_JJ our_PRP$ wallets_NNS on_IN their_PRP$ latest_JJS overpriced_VBN
        geegaws_NNS ._.
        Pharmaceutical_NNP companies_NNS may_MD be_VB evil_JJ incarnate_NN ._. And_CC we_PRP may_MD be_VB putty_NN in_IN their_PRP$ pecuniary_JJ
        little_JJ hands_NNS ._. But_CC that_DT has_VBZ nothing_NN at_IN all_DT to_TO do_VB with_IN the_DT question_NN of_IN whether_IN there_EX is_VBZ
        anything_NN wrong_JJ with_IN pursuing_VBG enhancement_NN ._. When_WRB Elliott_NNP eagerly_RB dons_VBZ his_PRP$ hair_NN shirt_NN to_TO
        bemoan_NN Big_NNP Pharma_NNP ,_, he_PRP finds_VBZ so_RB much_JJ sin_NN to_TO revel_VBP in_IN that_IN he_PRP forgets_VBZ to_TO give_VB a_DT reason_NN ,_, any_DT
        reason_NN ,_, why_WRB enhancement_NN is_VBZ ,_, in_IN itself_PRP ,_, immoral_JJ ._.
        At_IN most_JJS he_PRP presents_VBZ an_DT argument_NN for_IN keeping_VBG the_DT pharmaceutical_JJ industry_NN out_IN of_IN
        enhancement_NN ._. Okay_UH ,_, so_RB let_VB 's_POS take_VB Big_NNP Pharma_NNP out_IN of_IN the_DT picture_NN ._. If_IN we_PRP left_VBD the_DT
        encouragement_NN of_IN enhancement_NN to_TO the_DT government_NN ,_, the_DT military_NN ,_, schools_NNS ,_, foundations_NNS ,_,
        doctors_NNS ,_, or_CC parents_NNS ,_, would_MD this_DT now_RB be_VB morally_RB acceptable_JJ ?_. I_PRP think_VBP sometimes_RB it_PRP would_MD be_VB ._.
        And_CC nothing_NN that_IN Elliott_NNP says_VBZ provides_VBZ any_DT reason_NN to_TO think_VB otherwise_RB ._.
      
      
        Elliott_NNP 's_POS Response_NNP to_TO Caplan_NNP 's_POS Viewpoint_NN
        Caplan_NNP does_VBZ not_RB defend_VB medical_JJ enhancement_NN so_RB much_JJ as_IN attack_NN its_PRP$ critics_NNS ._. Or_CC rather_RB ,_, he_PRP
        attacks_VBZ a_DT small_JJ group_NN of_IN conservative_JJ critics_NNS who_WP want_VBP to_TO preserve_VB “ human_JJ nature_NN ._.” He_PRP
        dispatches_NNS those_DT critics_NNS with_IN admirable_JJ precision_NN ,_, but_CC I_PRP am_VBP not_RB sure_JJ why_WRB he_PRP believes_VBZ that_DT
        group_NN of_IN critics_NNS includes_VBZ me_PRP ._. My_PRP$ worry_VBP about_IN enhancement_NN technologies_NNS has_VBZ little_JJ to_TO do_VB with_IN
        human_JJ nature_NN ._. My_PRP$ worry_VBP is_VBZ that_IN we_PRP will_MD ignore_VB important_JJ human_JJ needs_NNS at_IN the_DT expense_NN of_IN
        frivolous_JJ human_JJ desires_NNS ;_: that_IN dominant_JJ social_JJ norms_NNS will_MD crowd_NN out_RP those_DT of_IN the_DT minority_NN ;_:
        that_IN the_DT self-improvement_JJ agenda_NN will_MD be_VB set_VBN not_RB by_IN individuals_NNS ,_, but_CC by_IN powerful_JJ corporate_JJ
        interests_NNS ;_: and_CC that_IN in_IN the_DT pursuit_NN of_IN betterment_NN ,_, we_PRP will_MD actually_RB make_VB ourselves_PRP worse_JJR
        off_RP ._.
        It_PRP 's_VBZ no_DT secret_NN that_IN many_JJ Americans_NNPS are_VBP deeply_RB ashamed_JJ of_IN their_PRP$ personal_JJ shortcomings_NNS and_CC
        inadequacies_NNS ._. Nor_CC is_VBZ it_PRP any_DT secret_NN that_IN these_DT shortcomings_NNS and_CC inadequacies_NNS can_MD be_VB
        exploited_VBN for_IN commercial_JJ profit_NN ._. But_CC do_VBP we_PRP really_RB want_VBP to_TO submit_VB our_PRP$ health-care_NN system_NN to_TO
        the_DT same_JJ forces_NNS that_WDT have_VBP made_VBN millionaires_NNS out_IN of_IN motivational_NN speakers_NNS and_CC diet_NN book_NN
        authors_NNS ?_.
        Skepticism_NNP about_IN enhancement_NN technologies_NNS is_VBZ not_RB equivalent_JJ to_TO a_DT wish_NN to_TO set_VB back_RB
        medical_JJ research_NN and_CC declare_VB some_DT applications_NNS off-limits_JJ ._. This_DT is_VBZ a_DT debate_NN about_IN enhancing_VBG
        human_JJ traits_NNS ,_, not_RB curing_VBG human_JJ illness_NN ._. To_TO say_VB that_IN our_PRP$ medical_JJ research_NN agenda_NN will_MD be_VB set_VBN
        back_RB if_IN we_PRP restrict_VBP enhancement_NN technologies_NNS makes_VBZ no_DT more_JJR sense_NN than_IN saying_VBG that_DT cancer_NN
        surgery_NN will_MD be_VB set_VBN back_RB if_IN the_DT American_NNP Broadcasting_NNP Corporation_NNP cancels_VBZ its_PRP$ cosmetic_JJ
        surgery_NN reality_NN TV_NN show_NN 
        Extreme_NNP Makeover_NNP ._.
        We_PRP live_VBP in_IN a_DT country_NN where_WRB 46_CD million_CD uninsured_JJ people_NNS cannot_NN get_VB basic_JJ medical_JJ care_NN ,_,
        while_IN the_DT rest_NN of_IN us_PRP spend_VBP a_DT billion_CD dollars_NNS a_DT year_NN on_IN baldness_NNS remedies_NNS ._. It_PRP is_VBZ not_RB just_RB
        the_DT inequity_NN here_RB that_WDT is_VBZ so_RB impressive_JJ ._. It_PRP is_VBZ the_DT fact_NN that_IN we_PRP have_VBP gotten_VBN so_RB accustomed_VBN
        to_TO the_DT inequity_NN that_IN we_PRP do_VBP not_RB see_VB it_PRP as_IN obscene_JJ ._.
      
    
  
